Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T21:28:56.695Z.
Calculation as of: 2026-10-06T21:28:56.695Z.
Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 77ffd79d43f0055242b38282a97f53e69ef3ec7586b4a3f7de15a7f16befe37a
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
SpyGlass Pharma, Inc. Common Stock
Market Cap
$828.48M
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$833.81M
EBITDA Yield
N/A
TTM Avg
3.15%
3Y Avg
3.15%
5Y Avg
3.15%
Market Cap
$838.62M
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$853.13M
EBITDA Yield
10.78%
TTM Avg
17.19%
3Y Avg
13.36%
5Y Avg
13.36%
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| SpyGlass Pharma, Inc. Common Stock (SGP) | $828.48M | N/A | N/A | N/A | N/A |
| Monte Rosa Therapeutics, Inc. (GLUE)vs › | $833.81M | N/A | 3.15% | 3.15% | 3.15% |
| Beta Bionics, Inc. (BBNX)vs › | $838.16M | N/A | N/A | N/A | N/A |
| Pacific Biosciences of California, Inc. (PACB)vs › | $838.62M | N/A | N/A | N/A | N/A |
| Ardelyx, Inc. (ARDX)vs › | $817.67M | N/A | 123.97% | 123.97% | 123.97% |
| Jade Biosciences, Inc. (JBIO)vs › | $816.13M | N/A | N/A | N/A | N/A |
| SL Science Holding Ltd (SLBT)vs › | $852.35M | N/A | N/A | N/A | N/A |
| InMode Ltd. (INMD)vs › | $804.16M | 16.94% | 14.19% | 12.45% | 9.40% |
| Rigel Pharmaceuticals, Inc. (RIGL)vs › | $853.13M | 10.78% | 17.19% | 13.36% | 13.36% |
| Alumis Inc. (ALMS)vs › | $855.38M | N/A | N/A | N/A | N/A |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
